Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Esaxerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA) approved in Japan in 2019, has been shown to reduce albuminuria in patients with diabetic nephropathy. However, evidence in non-diabetic patients with chronic kidney disease (CKD) remains limited. We investigated the efficacy and safety of long-term esaxerenone therapy in clinical practice, including both diabetic and non-diabetic patients.
This single-center, retrospective study included patients who received esaxerenone in addition to standard CKD therapy. Patients were followed for 18 months after treatment initiation. The urinary protein-to-creatinine ratio (UPCR), estimated glomerular filtration rate (eGFR), and serum potassium levels were regularly monitored at our outpatient department.
Seventeen patients were included in the analysis. The mean age was 60.5 years, and 11 patients did not have diabetes mellitus. Baseline eGFR ranged from 31.1 to 62.1 mL/min/1.73 m². The mean UPCR significantly decreased by 39% from 1.27 to 0.84 g/gCr at 18 months. Notably, all patients with a baseline UPCR > 1.0 g/gCr showed a reduction in UPCR. No correlation was observed between baseline eGFR and the percentage change in UPCR. The mean eGFR declined from 45.3 to 41.6 mL/min/1.73 m² at 6 months, consistent with previous reports, and showed minimal further decline thereafter. Serum potassium increased to 5.6 mEq/L in only one patient, and no serious adverse events were observed. Seven patients were receiving sodium–glucose cotransporter-2 (SGLT2) inhibitors at baseline and showed comparable reductions in UPCR.
Long-term treatment with esaxerenone demonstrated a sustained antiproteinuric effect in patients with CKD, including those without diabetes, with an acceptable safety profile. Given that reduction in proteinuria is recognized as a surrogate marker for future decline in kidney function, our findings suggest that esaxerenone may have beneficial effects across a broad range of patients with kidney impairment accompanied by proteinuria.
